Pharmacy

Top Medical News
DAPT with cilostazol reduces stroke recurrence without raising bleeding risk
5 minutes ago
Dual antiplatelet therapy (DAPT) using cilostazol appears to be more beneficial than single antiplatelet therapy, with the results of a study suggesting that DAPT helps lower the incidence of ischemic stroke recurrence without increasing the risk of severe or life-threatening bleeding.
Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?
Roshini Claire Anthony, 15 hours ago

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

Pharmacist-led collaborative gout clinic helps patients achieve serum uric acid goals
Stephen Padilla, 18 hours ago
A collaborative clinic led by a pharmacist helps patients with gout to attain better clinical outcomes in the management of their condition, even in the presence of renal impairment, reports a Singapore study. The clinic provides safe, stepwise increments of urate-lowering therapy (ULT) in addition to serum uric acid (SUA) monitoring and adherence reinforcement through frequent initial visits.
SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
Audrey Abella, 20 hours ago
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
Buprenorphine use during pregnancy linked to better neonatal outcomes
Elaine Soliven, 20 hours ago
The use of buprenorphine during pregnancy appears to be associated with a lower risk of adverse neonatal outcomes compared with methadone use. However, adverse maternal outcomes are similar for both therapies, according to a recent study.
Letrozole outperforms clomiphene citrate for ovulation induction
Yesterday
The use of letrozole for inducing ovulation in women with infertility and polycystic ovarian syndrome (PCOS) appears to yield improvements in ovulation, pregnancy, and live-birth rates as compared with clomiphene citrate, according to a study.
Sleep disturbances tied to day-before, split-dose PEG regimens for colonoscopy
Yesterday
Day-before and split-dose high-volume polyethylene glycol (PEG) regimens for patients scheduled to have a colonoscopy are associated with the greatest sleep disturbance, reports a Canada study.
Special Reports
The role of oral antivirals in COVID-19 treatment: Who, when, and how?
Dr. Roger Paredes, Dr. Nicola Petrosillo, Dr. Petrick Periyasamy, 30 Jan 2023

Though most countries have eased pandemic restrictions, there is no room for complacency in managing COVID-19, which continues to cause significant morbidity and mortality.

At a recent symposium, esteemed experts Dr Roger Paredes, Head of Department of Infectious Diseases at the Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, and Dr Nicola Petrosillo, Head of the Infection Prevention and Control and Infectious Disease Service at University Hospital Campus Bio-Medico, Rome, Italy, gave global perspectives on the continuing unmet needs in the COVID-19 outpatient landscape and discussed the role of antiviral treatment options in patients at risk of progressing to severe COVID-19. Dr Petrick Periyasamy, Head of Infectious Diseases Unit, Medical Department, UKM Medical Centre, Kuala Lumpur, Malaysia, chaired the session.

Product Highlight - Amnoz
30 Nov 2022
Amlodipine 5 mg and 10 mg tab
Product Highlight - Cruzor
30 Nov 2022
Irbesartan 300 mg FC tab
Product Highlight - Roxatin
30 Nov 2022
Rosuvastatin 10 mg and 20 mg FC tab
Timely treatment of patients at risk for severe COVID-19 prevents severe outcomes
Dr. Asok Kurup, Dr. Alex Soriano, 31 Oct 2022

Despite widespread uptake of vaccinations, COVID-19 remains a serious health issue for high-risk patients, owing to the emergence of new variants of concern (VOCs), waning immunity, and breakthrough infections.

At a recent symposium in Singapore, esteemed experts Dr Asok Kurup, Consultant Infectious Diseases Physician at Mount Elizabeth Medical Centre, Singapore, and Dr Alex Soriano, Head of Infectious Diseases Department, Hospital Clínic of Barcelona and Assistant Professor, University of Barcelona, Spain, gave insights on the evolution of global trends since the start of the COVID-19 pandemic and discussed key challenges in managing high-risk patients with COVID-19 in the ICU. They also highlighted early treatment strategies to minimize the burden of COVID-19 on healthcare systems.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 04 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Product Highlight - Idacio
13 Sep 2022
Adalimumab soln for inj 40 mg/0.8 mL
Conference Reports
Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?
Roshini Claire Anthony, 06 Feb 2023

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
Audrey Abella, 06 Feb 2023
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
130/80 home BP equivalent to clinic BP for stage 1 hypertension
Stephen Padilla, 03 Feb 2023
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Tislelizumab–chemotherapy combo poised as new first-line option for advanced gastric cancer
Jairia Dela Cruz, 03 Feb 2023
Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.
Preop chemotherapy confers survival advantage in colorectal cancer with liver metastasis
Jairia Dela Cruz, 02 Feb 2023
Giving chemotherapy to patients with synchronous and unresectable liver metastases from colorectal cancer before undergoing primary tumour resection helps boost survival outcomes, according to a phase III trial presented at this year’s ASCO Gastrointestinal Cancer Symposium (ASCO GI).
Durable benefits with beti-cel therapy in beta-thalassaemia
Elvira Manzano, 26 Jan 2023
One-time ex-vivo gene therapy with betibeglogene autotemcel (beti-cel) reduces the need for transfusion in patients with transfusion-dependent beta-thalassaemia in an analysis of studies presented at ASH 2022.
Efgartigimod tied to sustained platelet count increase in patients with ITP
Elaine Soliven, 24 Jan 2023
Treatment with efgartigimod, a neonatal Fc receptor (FcRn) antagonist, in patients with chronic or persistent immune thrombocytopenia (ITP) resulted in a higher proportion of patients achieving a sustained platelet count response compared with placebo, according to the ADVANCE IV* trial presented at ASH 2022.
Product Highlights
CME Modules